AI Article Synopsis
- A placebo-controlled trial examined the effectiveness of sulphasalazine (4-6 g per day) on patients with active Crohn's disease from August 1977 to August 1979, utilizing a nine-item inflammatory activity index for measurement.
- The inflammatory activity index included factors such as serum albumin, ESR, body weight relative to height, and other symptoms, with a favorable response defined as a 25% or more decrease in activity index at the end of the trial.
- Results showed that 26 patients were followed for six months, and those receiving sulphasalazine experienced a significantly better response than those who received a placebo.
Article Abstract
The response of active Crohn's disease to sulphasalazine (4-6 g per day) has been studied in a placebo-controlled trial. The study was carried out at two hospitals. From August 1977 to August 1979 all patients with established Crohn's disease were examined for their eligibility for the trial. A nine-item index of inflammatory activity was used as the primary measure of response. The variables in this index were serum albumin, ESR, body weight released to height, abdominal mass, temperature, stool consistency, bowel resection, and extraintestinal symptoms related to Crohn's disease. A favourable response to therapy was defined as a decrease of the activity index with 25% or more at the end of the trial period, compared with the initial value. Twenty-six patients (13 in each treatment group) have been followed up for six months. The response of active Crohn's disease to sulphasalazine was significantly better than to placebo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1419240 | PMC |
| http://dx.doi.org/10.1136/gut.22.5.404 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clonal Hematopoiesis of Indeterminate Potential in Crohn's Disease and Ulcerative Colitis.
Inflamm Bowel Dis
January 2025
Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1498, New York, NY 10029, USA.
Background: Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of somatic mutations in myeloid and lymphoid malignancy genes in the blood cells of individuals without a hematologic malignancy. Inflammation is hypothesized to be a key mediator in the progression of CHIP to hematologic malignancy and patients with CHIP have a high prevalence of inflammatory diseases. This study aimed to identify the prevalence and characteristics of CHIP in patients with inflammatory bowel disease (IBD).
View Article and Find Full Text PDFRadiation exposure in patients with inflammatory bowel disease.
J Crohns Colitis
January 2025
Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium and Department of Gastroenterology and Hepatology, University Hospitals Leuven, Belgium.
Background And Aims: Radiological imaging is crucial for diagnosing and monitoring patients with inflammatory bowel diseases (IBD). With increasing awareness of radiation risks, imaging doses should be 'as low as reasonably achievable', with a risk level that one should try to stay underneath 75 mSv. However, real-world data on cumulative exposure are limited.
View Article and Find Full Text PDFEffects of immune cells in mediating the relationship between inflammatory bowel disease and pyoderma gangrenosum: a two-sample, two-step mendelian randomization study.
Arch Dermatol Res
January 2025
Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Background: Although the precise cause of the co-occurrence of pyoderma gangrenosum (PG) and inflammatory bowel disease (IBD) is still unknown, prior research has shown that the two conditions coexist. Moreover, it is currently unknown how immune cells function in influencing the relationship between IBD and PG.
Methods: In order to choose independent single nucleotide polymorphism (SNP) as instrumental variables, we were provided with genome-wide association study (GWAS) summary data of European populations from the IEU OpenGWAS project (for IBD) and a the FinnGen database (for PG) publically available.
Inpatient Nutritional Considerations in Inflammatory Bowel Disease.
Curr Gastroenterol Rep
December 2025
St Luke's University Hospital, Fountain Hill, USA.
Purpose Of Review: This review aims to explain the causes, diagnosis, and treatment of malnutrition in hospitalized patients with inflammatory bowel disease (IBD), focusing on both adults and children.
Recent Findings: Malnutrition is common among IBD patients, affecting up to 85% of individuals, and is linked to higher rates of illness, death, and longer hospital stays. Recent studies highlight the importance of early detection using tools like the Subjective Global Assessment (SGA) and handgrip strength tests.
[Granulomas in Intestinal Biopsies? Intestinal Tuberculosis Mimicking Crohn's Disease: A Case Report].
Rev Med Chil
June 2024
Sección de Gastroenterología, Hospital Clínico Universidad de Chile, Santiago, Chile.
Intestinal tuberculosis is a bacterial infection that represents 10% of extrapulmonary tuberculosis. It is known as the great mimicker due to its clinical presentation similar to other diseases such as Crohn's Disease or Neoplastic Intestinal Disease. Its diagnosis is complex, given the paucibacillary characteristic of the disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!